Paxlovid

The spike protein on the SARS-CoV-2 virus up close

Protease inhibitor outperforms Paxlovid protecting lungs of mice

An oral drug developed by Stanford University researchers may be superior to Pfizer’s Paxlovid at reducing the severity of COVID-19, at least in mice.

Helen Floersh Mar 14, 2024 6:30am

Tonix redirects long COVID med toward fatigue after fail in pain

Sep 5, 2023 9:52am

How the test-to-treat pillar of the US COVID strategy is failing

Apr 15, 2022 2:50pm